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Edited by Gianni CesareniAbstract Activation-induced cell death (AICD) in activated T
lymphocytes is largely mediated by Fas/Fas ligand (FasL) inter-
action. The cytoplasmic adaptor molecule Fas-associated death
domain protein (FADD) plays an essential role in the apoptotic
signalling of the Fas death pathway. In the present study, we ob-
served that FADD deﬁcient (FADD/) Jurkat T cells undergo
AICD to a similar extent as wild-type cells. AICD in wild-type
Jurkat T cells is via apoptosis, whereas it is non-apoptotic in
FADD/ cells. The latter took up propidium iodide, exhibit a
loss in mitochondrial membrane potential and have no detectable
cleavage products of caspase-8 or -3 activation, suggesting that
these cells die by necrosis. Wild-type Jurkat T cells undergo
apoptosis when incubated with recombinant FasL and Trail but
not with TNF-a. In contrast, FADD/ Jurkat T cells are resis-
tant to FasL and Trail but die of necrosis when incubated with
TNF-a. We showed that neutralising anti-TNF-a blocked AICD
as well as TNF-a-induced necrosis in FADD/ Jurkat T cells.
Furthermore, downregulating the receptor interacting protein,
RIP, with geldanamycin treatment, which is essential for TNF-
a signalling, markedly inhibited AICD in FADD/ Jurkat T
cells. In addition, caspase-8-deﬁcient Jurkat T cells are resistant
to Fas- and TNF-a-induced cell death. Taken together, our re-
sults suggest that a deﬁciency in FADD and not caspase-8 or
the inhibition of the Fas signalling pathway sensitises Jurkat T
cells to TNF-a-dependent necrosis during AICD.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Activation-induced cell death1. Introduction
During an immune response, a majority of the T lympho-
cytes that undergo clonal expansion and proliferation in re-
sponse to antigens in vivo have to subsequently die to
maintain T cell homeostasis [1–3]. The physiological process
involved in the eﬃcient removal of these activated lymphocytes
is known as activation-induced cell death (AICD). In the im-
mune system, AICD acts as a feedback mechanism for termi-Abbreviations: FADD, Fas-associated death domain; MMP, mito-
chondrial membrane potential; AICD, activation-induced cell death;
TNF-a, tumour necrosis factor alpha; PMA, phorbol myristic acetate;
PHA, phytohaemaglutinin; RIP, receptor interacting protein
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doi:10.1016/j.febslet.2005.10.041nating an on-going immune response and also serves to
maintain peripheral T cell tolerance [4,5]. Unless survival sig-
nals are received, AICD may be a default pathway in all acti-
vated T lymphocytes.
It is well established that AICD in T lymphocytes occurs
predominantly by apoptosis mediated by the interaction of
the Fas antigen and the Fas ligand (FasL) on the cell surface
[6,7]. The Fas antigen is a death receptor belonging to the tu-
mour necrosis factor (TNF) receptor family [8]. The impor-
tance of Fas and FasL in AICD is underscored in mice
having mutations in either Fas (lpr mice) or FasL (gld mice):
abnormal T cells accumulate in the periphery of these mice
after about 8 weeks of age [9,10]. However, growing evidence
from a number of studies has shown that TNF-a and Trail
are also involved in AICD [6,11,12], which help to explain
the death of mature T cells from lpr mice following administra-
tion of either superantigens or speciﬁc peptide antigens to
TCR transgenic lpr mice [13,14]. Accumulating evidence from
a number of studies also suggests that the blocking of death
receptor pathways can result in AICD via caspase-independent
cell death or necrosis [15–18].
The Fas-associated death domain protein (FADD) is a cyto-
plasmic adaptor protein and plays an essential role in Fas-
induced apoptosis. Upon activation of the Fas receptor by
FasL, FADD is recruited to the receptor via its carboxy-termi-
nal death domain (DD) [19,20]. The amino-terminal death
eﬀector domain (DED) of FADD interacts with a homologous
DED within the prodomain of caspase-8 and acts as a plat-
form for caspase-8 recruitment [21,22]. Upon binding to
FADD, caspase-8 is activated by proximity-induced activation
and this results in the activation of downstream eﬀector casp-
ases, such as caspase-3, -6 and -7. Once activated, these eﬀector
caspases mediate the degradation of various cellular compo-
nents important for cell structures and integrity, resulting in
the characteristic features of apoptosis. Because of the pivotal
role which FADD plays in the apoptotic signalling of death
receptors, mice with T cells that have germ line deﬁciency in
FADD or those carrying a dominant negative form of FADD
(FADDdd) are resistant to apoptosis mediated by death recep-
tors [23,24]. Although these mice lack all forms of death recep-
tor-mediated apoptosis they do not develop severe
lymphoproliferative disorders and autoimmune diseases as
seen in the lpr and gld mice. This suggests that alternative
death pathways exist for the removal of activated T lympho-
cytes to maintain homeostasis and T cell tolerance in these
mice. Alternatively, the lack of lymphoproliferative disorders
in these mice could be due to the inability of their T cells to
proliferate when activated with antigens [23,25]. However,ation of European Biochemical Societies.
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activated to divide, but the percentage of cells that die follow-
ing each round of cell division is increased and the cumulative
result is a lack of proliferation [15,26]. These results suggest
that T cells from FADDdd mice are more susceptible to pre-
mature cell death following T cell activation, and that a
FADD-independent pathway(s) is involved in the regulation
of AICD in these mice.
In the present study we have used FADD/ Jurkat T cells to
investigate the cell death pathways that underlie FADD-
independent AICD. Our results demonstrated that FADD/
Jurkat T cells still undergo AICD to the same extent as wild-
type cells but they die by necrosis instead of apoptosis. FADD
but not caspase-8 deﬁciency sensitises Jurkat T cells to die of
necrosis when incubated with TNF-a. We showed that AICD
in FADD/ Jurkat T cells involved TNF-a and is dependent
on the receptor interacting protein, RIP. In summary, a loss
of FADD sensitises Jurkat T cells to TNF-a-dependent necro-
sis during AICD.2. Materials and Methods
2.1. Materials
Phytohaemaglutinin (PHA), phorbol myristic acetate (PMA), iono-
mycin, phenazine metasulfate (PMS), propidium iodide (PI) and anti-
a-tubulin were purchased from Sigma (UK). MTS reagent was from
Promega (UK) and Hoechst 33358 from Molecular Probes (UK).
The caspase inhibitor z-VAD-FMK was from Bachem (UK) and
was prepared as a 50 mM stock solution in DMSO. Polyclonal rabbit
antibodies to caspase-8 and -3 were generous gifts from Xiao-Ming
Sun, MRC Toxicology Unit (UK). Anti-RIP was obtained from BD
Pharmingen (UK). The antibodies to PARP and recombinant human
FasL were obtained from Alexis (UK). Recombinant TRAIL and
TNF-a were generous gifts from Nick Harper, MRC Toxicology Unit.
Neutralising anti-TNF-a was purchased from R&D systems (UK) and
geldanamycin was from Calbiochem (UK). HRP-conjugated second-
ary antibodies were purchased from DAKO.
2.2. Cell culture
Wild type (clone A3), caspase-8/ and FADD/ Jurkat T cells
were a gift from Dr. J. Blenis (Harvard Medical School, US) [27,28].
Both caspase-8/ and FADD/ Jurkat T cells were conﬁrmed to lack
caspase-8 and FADD, respectively, using Western blot analysis (results
not shown). Cell cultures were maintained in logarithmic phase of
growth in RPMI 1640 (Gibco BRL, Paisley, UK) supplemented with
10% FCS and 2 mM L-glutamine (complete medium) in an atmosphere
of 5% CO2 at 37 C. To induce AICD in Jurkat cells, 1 · 106 cells/ml in
complete medium were stimulated with either 5 lg/ml PHA or co-stim-
ulated with PMA (10 ng/ml) and ionomycin (200 ng/ml) for 16 h at
37 C in an incubator.2.3. Cell viability assay
Cell viability was assessed by the Cell Titer 96TM Aqueous cell pro-
liferation assay (MTS) as previously described [29]. In brief, aliquots of
100 ll cell suspension (1 · 105 cells) were dispensed into the wells of a
96-well ﬂat-bottomed plate followed by the addition of 20 ll freshly
prepared MTS/PMS solution to each well with the appropriate blank
(complete medium alone). The plate was incubated at 37 C in an incu-
bator for 2 h before reading absorbance at 490 nm using an ELISA
plate reader. All samples were assayed in triplicate. The MTS/PMS
solution was prepared by mixing 5 parts of MTS (2 mg/ml in PBS)
to 1 part of PMS (0.92 mg/ml in PBS) just before used. The percentage
of cell viability is calculated as follows:
Cell viability ¼ ðabsorbance of treated cells blankÞ=
ðcontrol absorbance blank 100Þ.2.4. UV microscopy
Necrosis and apoptosis in Jurkat T cells were determined using
UV microscopy [29]. In brief, treated cells were harvested and
washed with PBS before resuspending in 150 ll PBS containing
15 lg/ml PI for 2 min in the dark. Thereafter, the cells were washed
of excess PI and ﬁxed in 200 ll ice-cold methanol for 15 min prior
to staining with 2.5 lg/ml Hoechst 33358 for 15 min. The stained
cells were centrifuged down and resuspended in glycerol/PBS (50/
50, v/v) before mounting on slides and viewed using ﬂuorescence
microscopy. Cells were scored as apoptotic if they displayed charac-
teristic chromatin condensation and/or nuclear fragmentation
stained by the Hoechst 33358 dye or necrosis if they were stained
with PI and do not display apoptotic morphology. Between 500
and 600 cells were scored for each sample.2.5. Detection of mitochondrial membrane potential using ﬂowcytometry
To determine the loss of mitochondrial membrane potential (MMP),
treated Jurkat T cells were washed and incubated with 0.1 lM TMRE
for 15 min at 37 C. Cells were then washed twice with ice cold PBS
and resuspended in 1 ml PBS before analysing using ﬂowcytometry
(FACS Calibur: Becton Dickinson). Normal cells with intact MMP
accumulate TMRE in the mitochondria and exhibit high ﬂuorescence
intensity, whereas a loss of MMP in a cell is depicted by a decrease in
the ﬂuorescence intensity, as TMRE is no longer able to accumulate in
the mitochondria.2.6. Western blotting
This is essentially as described previously [29]. After treatment,
2 · 106 cells were washed in PBS and then resuspended in 30 ll lysis
buﬀer (0.1 M NaCl, 1 mM Tris–HCl at pH 7.6, 1 mM EDTA, 1% Tri-
ton-X, 1 mM PMSF) and taken through 3· freeze/thaw cycles on dry
ice and samples for PARP analysis were sonicated instead. Protein
concentration was measured using the Bradford assay (Biorad, Ger-
many). 20 lg protein from whole-cell lysates was diluted in loading
buﬀer (2% SDS, 10% glycerol, 50 mM Tris–HCl, pH 6.8, 0.2% Bromo-
phenol Blue, 100 mM DTT and 4 M Urea for PARP analysis) and re-
solved using 13% SDS–PAGE (caspase-8 and -3) or 7% SDS–PAGE
(PARP and RIP). The separated proteins were transfer onto Hybond
C membrane (Amersham, UK) using a semi-dry transfer system (Bio-
rad) and probed with antibodies to caspase-8, -3, PARP, RIP and
a-tubulin. Detection was carried out using chemiluminescence (Amer-
sham).3. Results and discussion
AICD is a physiological process for the maintenance of T
cell homeostasis in the immune system and involves the eﬃ-
cient removal of activated T lymphocytes that accumulate dur-
ing clonal expansion and proliferation in response to antigens.
Although the involvement of the Fas-pathway in AICD is well
documented, accumulating evidence suggest that Trail and
TNF-amay have a role in the maintenance of T cell homeosta-
sis [6,7,11,12]. Central to the apoptotic signalling pathway of
these death receptors is the adaptor protein, FADD, which
plays an essential role in death receptor-mediated apoptosis.
However, AICD still occurs in mice that lack FADD or have
FADDdd in the T cells [23,24], indicating the existence of
FADD-independent alternative death pathways for the re-
moval of clonally expanded T cells during immune response
in these mice [15,26].
In the present study, we have used Jurkat T cells deﬁcient in
FADD to investigate the alternative pathways that underlie
FADD-independent AICD in T lymphocytes. We used PHA
or co-stimulation with PMA and ionomycin as T cell receptor














































































Fig. 1. FADD/ Jurkat T cells undergoing AICD via necrotic cell death. Wild-type and FADD/ Jurkat T cells were left untreated (control) or
treated with either PHA or co-treated with PMA and ionomycin (Ion) for 16 h. Cell viability (A), cells with loss MMP (B), apoptotic (C) and PI
positive cells (D) were determined as described in Section 2. The results are the means ± S.E.M. from 3 independent experiments.
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16 h readily undergo AICD as shown by decreased cell viabil-
ity. The FADD/ Jurkat cells also exhibited a similar extent
of cell death following treatment with these stimuli. Both wild
type and FADD/ T Jurkat cells exhibit a loss in MMP fol-
lowing AICD (Fig. 1B). Since a number of studies have shown
that Jurkat T cells deﬁcient in FADD or overexpressing dom-
inant negative FADD undergo necrosis when given apoptotic
stimuli [17], we examined the mode of cell death in FADD/
cells following AICD. As illustrated in Fig. 1C and D, AICD
in wild-type Jurkat cells was apoptotic as indicated by the con-
densed and fragmented nuclei (Fig. 1C). However, no apopto-
tic morphology was detected in AICD of FADD/ Jurkat
cells, although greater than 50% of the cells took up PI, indi-
cating that these cells may have died by necrosis (Fig. 1D).
A large proportion of wild-type Jurkat cells were also stained
positive for PI, but this necrotic death is secondary to apopto-
sis since the PI positive cells also exhibit apoptotic nuclei mor-
phology. To conﬁrm that AICD in FADD/ cells is necrotic
and not apoptotic we examined whether caspases are activated
in these cells. As illustrated in Fig. 2A, the broad-spectrum cas-
pase inhibitor, z-VAD-FMK inhibited cell death in wild type
but not FADD/ Jurkat T cells stimulated with PHA or
co-stimulated with PMA and ionomycin (Fig. 2B). In agree-
ment with this result, we could not detect any cleavage prod-
ucts of caspase-8 or -3 in Western blot analysis and PARP, a
substrate for caspase-3 remained intact in FADD/ cells
undergoing AICD (Fig. 2C). However, in wild-type Jurkat T
cells, both caspase-8 and -3 were cleaved to their respective ac-tive fragments and PARP, a substrate of caspase-3, was
cleaved from the 116 kDa form to the 85 kDa fragments. All
these characteristics of apoptosis were abrogated in the pres-
ence of z-VAD-FMK. Recently, a number of studies have
shown that blocking apoptosis with caspase inhibitors,
switched cell death from apoptosis to necrosis [17,18,31]. We
found a small increased in necrotic cells (10%) in wild-type
Jurkat cells activated by PHA but not when co-treated with
PMA and ionomycin in the presence of z-VAD-FMK (results
not shown).
To characterise the cell death pathway(s) involved in AICD
of FADD/ Jurkat T cells, we examined the propensity of
these cells to undergo cell death when incubated with recombi-
nant FasL, Trail and TNF-a. As shown in Fig. 3A, wild-type
Jurkat cells are extremely sensitive to Fas activation with more
than 80% cell death after 16 h incubation with FasL. However,
these cells appeared not to be sensitive to TRAIL or TNF-a
after 16 h treatment. Prolonging the incubation time to 24 h
did promote cell death with Trail but not with TNF-a. This
is not surprising, since wild-type Jurkat T cells will only under-
go TNF-a-induced cell death when pre-treated with cyclohexa-
mide to block protein synthesis (results not shown). In
contrast, FADD/ cells are resistant to both FasL and Trail,
and prolonging the incubation time to 24 h did not promote
any further cell death (results not shown). However, unlike
wild-type Jurkat T cells, FADD/ cells do undergo cell death
when incubated with TNF-a alone (Fig. 3A). This suggests
that TNF-a maybe involved in the AICD of FADD/ Jurkat
T cells and the sensitisation of these cells to the cytokine is
Fig. 2. AICD in FADD/ Jurkat T cells is caspase-independent. Wild-type (A) and FADD/ (B) Jurkat T cells were treated with either PHA or
co-treated with PMA and ionomycin in the presence or absence of z-VAD-FMK (50 lM) for 16 h and cell viability determined. The results are the
means ± S.E.M. from 3 independent experiments. (C) Following treatments, 20 lg protein of whole-cell lysates were resolved by SDS–PAGE,
transferred onto nitrocellulose membrane and then probed with antibodies to caspases-8, -3 and PARP. Results shown are one representative of
three.
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by TNF-a in FADD/ Jurkat T cells appears to be necrotic as
no apoptotic nuclei were detected (Fig. 3B and C).
To determine whether TNF-a was involved in AICD of
FADD/ Jurkat T cells, neutralising anti-TNF-a was added
to cell cultures treated with PHA or co-stimulated with PMA
and ionomycin. As shown in Fig. 4A, the presence of TNF-a
neutralising antibodies has a marked protective eﬀect onFADD/ cells co-treated with PMA and ionomycin, but the
protection was only partial for PHA treatment. Taken to-
gether, these results suggest that the TNF-a-pathway is domi-
nant in AICD induced by the co-stimulation with PMA and
ionomycin but is only partially involved with PHA stimulation
in FADD/ Jurkat cells. The involvement of TNF-a in AICD
has previously been shown to occur in mature T cells [32]. To


























































Fig. 3. FADD/ Jurkat T cells but not wild-type cells are sensitive to
TNF-a. (A) Wild-type and FADD/ Jurkat T cells were treated with
FasL, TRAIL and TNF-a for 16 h and cell viability determined.
Apoptotic (B) and necrotic cells (C) from wild type and FADD/
Jurkat T cells stimulated with TNF-a were quantiﬁed and the results
are the means ± S.E.M. from 3 independent experiments.
Fig. 4. AICD in FADD/ Jurkat T cells involves TNF-a and RIP.
(A) FADD/ Jurkat T cells were treated PHA or co-stimulated with
PMA and ionomycin (Ion) in the presence or absence of neutralising
anti-TNF-a for 16 h. (B) FADD/ Jurkat T cells were treated with
geldanamycin (GA) for 24 h and RIP expression determined using
Western blotting. To ensure equal amount of protein were loaded, a-
tubulin level in the same blot was reprobed with anti-a-tubulin.
(C) Geldanamycin-treated FADD/ Jurkat T cells were activated with
PHA or co-stimulate with PMA and ionomycin (Ion) or TNF-a for
16 h and cell viability determined. The results are the means ± S.E.M.
from 3 independent experiments.
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interacting protein (RIP), which is a necessary component
for TNF-a-signalling and the induction of necrosis [17]. RIP
is known to interact and form a stable complex with heat
shock protein HSP90, and the disruption of this complex with
the anti-tumour drug, geldanamycin leads to RIP degradation
[17,33]. In FADD/ Jurkat T cells treated with geldanamycin,
there was a marked reduction in the endogenous level of RIP
(Fig. 4B) as reported previously [17,33]. With the level of RIP
reduced, there is a concomitant decrease in AICD in FADD/
 Jurkat cells, which was most evident when co-stimulated
with PMA and ionomycin, albeit less with PHA (Fig. 4C).
The latter further indicate that TNF-a is only partially in-
volved in PHA-induced AICD (Fig. 4A). As expected, TNF-
a-induced cell death in FADD/ Jurkat T cells was alsoinhibited by the downregulation of RIP (Fig. 4C), conﬁrming
the important role of RIP in TNF-a signalling and reinforces
the involvement of TNF-a during AICD in these cells when
co-stimulated with PMA and ionomycin. Our results indicate
that RIP is able to mediate the signal transduction pathway
6470 C.P. Lawrence, S.C. Chow / FEBS Letters 579 (2005) 6465–6472of TNF-a in the absence of FADD, suggesting that RIP can
directly interact with TNFR1 in Jurkat T cells.
Although our results suggested that FADD deﬁciency
could sensitise Jurkat T cells to TNF-a-induced cell death,
we cannot rule out the possibility that the inhibition of the
Fas-signalling pathway itself by the lack of FADD may cause
this sensitisation. In order to rule out the possibility that
blocking of Fas-signalling per se sensitises Jurkat T cells to
TNF-a, we examined the eﬀect of caspase-8 deﬁciency in
AICD in Jurkat T cells. Because the binding of caspase-8
to FADD mediates the apoptotic-signalling pathway of
Fas, deletion of caspase-8 or FADD would inhibit the Fas-
signalling pathway. Caspase-8 is the proximal protease in
the caspase cascade induced by Fas and the downstream
eﬀector caspases are responsible for the degradation of cellu-
lar components during apoptosis. As shown in Fig. 5A,
PHA-treatment induced cell death in caspase-8/ Jurkat T
cells, albeit less compared to wild-type or FADD/ cells
(Fig. 1). Similar to FADD/ Jurkat T cells, cell death in
caspase-8/ cells induced by PHA was necrosis and no
apoptotic cells were detected (Fig. 5B and C). However,
caspase-8/ cells were completely resistant to cell death in-
duced by co-stimulation with PMA and ionomycin and TNF-
a (Fig. 5A). This suggests that caspase-8/ Jurkat T cells do
not respond in the same manner as FADD/ cells to AICD.


















































Fig. 5. Caspase-8/ Jurkat T cells are sensitive to AICD induced by
PHA but not when co-treated with PMA and ionomycin. (A) Caspase-
8/ Jurkat T cells were treated with PHA or co-stimulated with PMA
and ionomycin (Ion) for 16 h and cell death was determined.
Apoptotic (B) and necrotic cells (C) from caspase-8/ cells stimulated
with PHA for 16 h were determined as described in Section 2. The
results are the means ± S.E.M. from 3 independent experiments.caspase-8/ cells were activated with PHA in the presence of
neutralising anti-TNF-a. As illustrated in Fig. 6A, the presence
of neutralising anti-TNF-a has no eﬀect on PHA-induced
AICD. Furthermore, downregulating RIP (Fig. 6B) also failed
to protect caspase-8/ cells from PHA-induced necrosis
(Fig. 6C), conﬁrming that TNF-a is not involved in PHA-in-
duced necrosis in caspase-8/ Jurkat cells. Taken together,
these results suggest that TNF-a only induced necrotic cell
death in Jurkat T cells that are deﬁcient in FADD and not cas-
pase-8 or the blocking of Fas-signalling.
Although caspase-10 have been recruited and activated at
the Fas death-inducing signalling complexes (DISC) in Jurkat
T cells [34], it is unlikely to be involved in PHA-induced
AICD. As shown in Fig. 5B and C, cell death induced by
PHA is necrotic and was unaﬀected by the presence of the
pan-caspase inhibitor, z-VAD-FMK (Fig. 6D). This suggests
that PHA-induced AICD in caspase-8/ null cells is cas-
pase-independent and unlikely to involve caspase-10. Our re-
sults are very much in line with the recent observations
where the overexpression of caspase-10 in caspase-8/ Jurkat
T cells cannot functionally replace caspase-8 in Fas-induced
cell death [34]. This suggests that an additional death pathway
maybe involved in PHA-induced AICD in Jurkat T cells. One
possibility is the caspase-independent cell death pathway in-
duced by anti-CD2 in T lymphocytes [35]. Since PHA activates
by cross-linking T cell surface receptors, it is possible that CD2
may be activated during the agglutination and polyclonal acti-
vation of T cells by the lectin. We also found that the antiox-
idant, butylated hydroxyanisole (up to 100 lM) has no eﬀect
on PHA-induced cell death in caspase-8/ Jurkat cells sug-
gesting that free reactive oxygen species are not involved (re-
sults not shown).
In recent years, a number of in vitro studies have demon-
strated that the triggering of death receptors in T lymphocytes
can lead to necrotic cell death [15–17]. However, it is not clear
whether necrosis plays any role in AICD during T cell homeo-
stasis following an immune response in vivo. Necrosis is often
regarded as an acute non-physiological injury, characterised by
swelling of the cell and disruption of its membrane integrity
leading to an inﬂammatory reaction. Although both necrotic
and apoptotic cells are taken up by antigen presenting cells,
only necrotic cells are capable of activating dendritic cells to
trigger T cell activation [36]. However, when both apoptotic
and necrotic cells are taken up by macrophages, the immuno-
suppressive eﬀect of apoptotic cells such as the production of
IL-10, TNF-b and PGE2 dominates [37,38]. With only necrotic
cells, the uptake will augment macrophage activation to secrete
proinﬂammatory cytokines, IL-6 and TNF-a [37,38], which
are likely to have an impact on the outcome of the immune re-
sponse. Furthermore, too much necrosis may also leads to
autosensitisation as the release of proinﬂammatory products
and contents from necrotic cells may signal immunologic
‘‘danger’’, and pushes the balance from tolerance to sensitisat-
ion in autoreactive T cells [39].
In conclusion, we have established that FADD deﬁciency
switches cell death from apoptosis to necrosis in Jurkat T cells
during AICD. A lack of FADD and not caspase-8 or the inhi-
bition of the Fas-pathway, sensitises Jurkat T cells from being
TNF-a resistant to become sensitive to the cytotoxic action of
this cytokine during AICD. This sensitisation to TNF-a in
FADD/ cells is not dependent on the inhibition of protein
synthesis.
Fig. 6. PHA-induced AICD in caspase-8/ Jurkat T cells is independent of TNF-a or caspases. (A) Caspase-8/ Jurkat T cells were treated with
PHA in the presence or absence of neutralising anti-TNF-a for 16 h. (B) Caspas-8/ cells were pre-treated with geldanamycin (GA) for 24 h and the
cells were analysed for RIP expression using Western blotting. To ensure that the protein concentrations loaded are equivalent, a-tubulin level in the
same blot was reprobed with anti-a-tubulin. (C) Geldanamycin-treated cells were activated with PHA for 16 h and cell viability determined.
(D) Caspase-8/ cells were stimulated with PHA in the presence or absence of z-VAD-FMK (50 lM) for 16 h and cell viability determined. The
results are the means ± S.E.M. from 3 independent experiments.
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